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This study compared the association of diﬀering methods of dementia ascertainment, derived from multiple sources, with nursing
home(NH)estimatesofprevalenceofdementia,lengthofstay,andcostsanunderstudiedissue.Subjectswere2050newadmissions
to 59 Maryland NHs, from 1992 to 1995 followed longitudinally for 2 years. Dementia was ascertained at admission from charts,
Medicare claims, and expert panel. Overall 59.5% of the sample had some indicator of dementia. The expert panel found a higher
prevalence of dementia (48.0%) than chart review (36.9%) or Medicare claims (38.6%). Dementia cases had lower relative average
per patient monthly costs, but longer NH length of stay compared to nondementia cases across all methods. The prevalence of
dementia varied widely by method of ascertainment, and there was only moderate agreement across methods. However, lower
costs for dementia among NH admissions are a robust ﬁnding across these methods.
Copyright © 2009 Ann L. Gruber-Baldini et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
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1.Introduction
Between 25–74% of all nursing home (NH) residents have
Alzheimer’s disease or related dementias [1–12]. Estimates
of the prevalence of dementia can vary widely, depending
on the diagnostic criteria used, source of information for
diagnosis, and the population of interest [13]. Studies that
use more detailed diagnostic interviews [7] typically ﬁnd
higher prevalence than chart documentation [14].
Just as the prevalence of dementia can vary, estimates of
costs from dementia can vary substantially as well. National
estimates, all from the 1990s, of the total cost of caring for
persons with dementia in the US range from $54 to $120
billion per year [15–18]. Per case dementia cost estimates
also vary widely, ranging from $11700 to $174000 per
year [17–20]. Although families provide substantial care for
individuals with dementia, state and federal governments
are responsible for acute medical care and assume a large
responsibility for long-term institutional care, primarily
through coverage by Medicare and Medicaid.
One study looking at costs for dementia care for
community-dwelling elderly [21] found an incremental cost
of dementia of $6927 U.S. dollars per year to Medicare,
mostly due to hospitalization; costs for dementia care in2 International Journal of Alzheimer’s Disease
long-term care settings are likely to be even higher. In 2000,
the total payment to NHs for care was $92.2 billion; of
this, 10% came from Medicare ($9 billion) and 48% from
Medicaid ($44.3 billion) [22]. Surprisingly, very few studies
have focused on the costs of care for NH residents with
dementia, despite the fact that 75% of all persons with
dementia will eventually reside in an NH [23], and the
greatest burden of public expenditures for formal care of
those with dementia occurs among those residing in NHs
[24]. Those few studies that have looked at NH costs for
dementia [21, 25, 26] have failed to examine the diﬀerential
cost of treating those with dementia, compared to those
without dementia, once in a nursing home setting.
Earlierstudiesofthecostsofdementiahavereliedheavily
on diagnostic information contained in the medical record
of NH residents or in the Minimum Data Set (MDS) ﬁles.
Large national studies, such as the Medical Expenditures
Panel Study (MEPS) [12], which base ﬁndings on the
MDS, underestimate rates of dementia by as much as 30%
[14]. Others, such as the National Medical Expenditures
Study (NMES) [15] relied on nurses’ reports of chart-
based diagnoses. These, too, have limitations in that they
are not obtained by any consistent diagnostic standard and
underestimate the true prevalence of dementia [27]. Smaller
studies of costs have been able to use other methods, which
include mental status testing [16, 17, 19, 23], but these
studies are limited because low functioning on mental status
testsisonlyoneaspectofadementiadiagnosis[27,28].None
of these studies have directly compared costs of dementia
versus non-dementia cases.
In addition to charts and mental testing, diagnostic
information from Medicare claims has also been used to
examine cost diﬀerence between those with and without
dementia in community settings. However, Medicare data
may also greatly underestimate the prevalence of dementia
and provide biased estimates of the impact of dementia. Two
studies (not in NHs) have compared data from Medicare
claims ﬁles within a group of community-dwelling elderly
with dementia. Both studies have found undercounts of
dementia cases ranging from 20% [29] to 87% [30]a m o n g
patients with known Alzheimer’s disease. A more recent
study [31] explored the correspondence of Medicare claims
of dementia to survey data and brief cognitive screening
in 5089 community-dwelling elderly. They also found that
5 years of Medicare claims captured the largest number of
dementia cases (562/855 = 65.7%), but that there was sub-
stantial nonoverlap in diagnoses (kappa between Medicare
and survey report = 0.41, 76% agreement).
No research, to our knowledge, has examined the
correspondence of the dementia diagnosis in the NH chart
with prior Medicare claims, and none has compared claims
and charts to a “gold standard” dementia diagnosis, such
as an expert panel. Therefore, this study will compare
dementia diagnosis derived from Medicare data in the year
prior to NH admission with both NH chart data and
with a dementia diagnosis ascertained by an expert panel.
This expert panel included neurologists, psychiatrists, and
a geriatrician, who followed a standardized protocol and
used DSM-III-R criteria for a diagnosis [14]. Diﬀerences in
the prevalence, characteristics of dementia cases at baseline,
and Medicare costs per month while in the initial NH are
examined by these alternate sources of dementia diagnosis.
By doing so, this study will permit comparison of the
eﬀect of diﬀerent approaches in estimating the prevalence of
dementia on cost estimates of the disease.
This study relies on data from an existing epidemiologic
nursing home admissions cohort [14, 32]. The original
study was designed with the hypotheses that (1) there is
a large under-recognition of dementia in NHs and hence
the reliance on the panel methodology to determine cases
in the study, and (2) that residents with dementia entering
a nursing home would die at a higher rate and develop
more adverse health events than residents without dementia.
Underlyingthissecondhypothesiswasthefactthatdementia
can reduce capacity to perceive and report early symptoms,
participate in treatment decisions, and adhere to treatment
recommendations [33, 34]. Consequently, nursing home
staﬀ may be less able to intervene early [34], as care may be
providedonlyafterobservingseveresymptoms[34,35].This
delay may result in more serious medical problems, more
extensive treatment, and increased mortality. Our previous
work[14,32]hasnotsupportedthishypothesisonmortality,
adverse medical events, or Medicare costs using a panel
determination of dementia, so we wanted to test whether
the source of the dementia determination would impact our
ﬁndings. It would be possible that cases that are recognized
by nursing home staﬀ to have dementia (chart-documented
cases) may be more severe than those unrecognized by
staﬀ (research panel cases), leading to communication
and adherence diﬃculties, and/or that the recognition of
dementia creates more potential treatment bias based on
negative perceptions about residents with dementia.
2.DesignandMethods
2.1. Sample. The sample for this analysis was 2050 residents,
ages 65 and older, newly admitted between September 1992
and March 1995 to 59 Maryland NHs who had complete
chart abstractions (capturing the ﬁrst 2weeks of the NH
stay) and Medicare claims (for 360days preceding admission
through 30days afterwards). The 59NHs were randomly
selected from 221NHs in the state and recruited within
each of 15 strata, deﬁned by ﬁve regions and bed size
(< 50, 51–150, > 150), such that the proportion of beds
represented for each stratum was approximately the same
as that stratum’s proportion of all beds statewide. Sixty-four
facilitieswereeventuallycontactedtoparticipateinthestudy.
Four (6%) refused to participate, and one facility that agreed
to participate had no new admissions over the course of the
study. A more detailed description on the methods of the
parent study may be found elsewhere [14].
The overall sample of the parent study included 2285
residents at baseline, from a total of 3283 eligible subjects, of
whom 30% refused participation [14]. Residents age 65years
andolderwhohadnotresidedinanursingfacilityorchronic
care facility for 8 or more days in the previous year were
eligible.Allparticipantswerefolloweduntildischarge,death,
or for up to two years after initial enrollment. The protocolInternational Journal of Alzheimer’s Disease 3
for the initial study, chart follow-up, and the additional of
Medicare claims was approved by the Institutional Review
Board of the University of Maryland Baltimore. Of the 2285
residents in the study, 2050 (89.7%) were matched with
Medicare claims records and are included in these analyses.
More detail on the methods of examining Medicare costs in
this sample is available in a previously published paper [32].
2.2. Measures
2.2.1. Dementia Determination. Panel dementia status was
determined in accordance with Diagnostic and Statistical
Manual III-R criteria [36] by an expert panel of geriatric
psychiatrists, neurologists, and a geriatrician. A detailed
description of the dementia ascertainment methodology is
found elsewhere [27]. Brieﬂy, two panelists (one neurologist
and one psychiatrist) rendered independent diagnoses in
three categories: dementia, no dementia, or diﬃcult to
diagnose. If they agreed, that was the determination. When
there was disagreement (n = 526), the case was brought to
a full panel discussion with 2 neurologists, 2 psychiatrists,
and a geriatrician. The geriatrician convened the conference
and adjudicated the ﬁnal diagnosis. The cases classiﬁed as
“diﬃcult to diagnose” were added to the “no dementia”
group for purposes of this report. Information used for
dementia diagnosis included previous and current cognitive
and functional status, in addition to demographic character-
istics and aﬀective, social, and behavioral status [14].
Chart diagnoses of dementia (presence versus absence)
was coded from NH chart records (including nursing
note, physician orders, admission sheets, medication orders,
but excluding the MDS) from the ﬁrst two weeks of
the NH stay. Complete copies of the baseline NH chart
were photocopied and coded by a research abstractor for
diagnosisofAlzheimer’sdiseaseorotherdementias.Multiple
dementia etiologies could be noted. Other mentions of
cognitive/memory impairment and senility in the ﬁrst two
weeks were noted separately and coded, but not included
in the dementia category for these analyses. Charts were
available for 2273 of the 2285 residents (99.5%) at baseline.
Designation of dementia from the Minimum Data Set
(MDS)wasalsoavailableformostsubjects(86%ofbaseline).
This measure was obtained from a checklist of medical con-
ditions on the MDS, including any indication of Alzheimer’s
diseaseorotherdementias.Previousworkinthissample[37]
has shown that the MDS dementia coding in this sample
corresponded highly with chart diagnosis (89% agreement,
kappa = 0.78). Thus, the MDS diagnosis was not included
in further analyses (as it is fairly redundant with the chart
information).
Medicare diagnosis of dementia was obtained from
any indication using ICD-9-CM codes 290.0-3 or 290.9
(senile, presenile, and degenerative dementia), 290.4 (vas-
cular/arteriosclerotic dementia), 294–294.9 (amnestic syn-
drome, organic brain syndrome, or dementia listed in
other conditions), and/or 331–331.9 Alzheimer’s Disease or
cerebral degeneration (there were no codes for 331.1 Pick’s
disease). Codes were associated with all the Medicare claims
(Part A and Part B) in the 360 days preceding NH admission
or during the month of admission. The coding system
combined codes from Martin et al. [26]a n dT a y l o re ta l .[ 30]
for dementia. Acute delirium and “dementias speciﬁcally
associated with (as a result of) other diseases” (as coded in
ICD-9-CM) were not included. Medicare claims allow one
principal ICD-9-CM diagnosis code to be submitted with a
claim;Medicareallowedupto14additionalcodesduringthe
timeframeweused(1992–1995).Diagnosiscodescamefrom
forms UB92 and HCFA 1500; all claims have one of these
forms. Thus, if a diagnosis is reported, it should have been
captured. There were a total of 1 097 313 Medicare records
used to capture these diagnoses, of which 30 349 (2.8%) had
any diagnosis of dementia.
We initially included ICD code “797” (senility without
mention of psychosis) per the work of others [26, 30,
38]. However, this code that was found on only 0.8% of
claims and in only 1.8% of our sample had little impact
on prevalence, but slightly decreased speciﬁcity. It was
subsequentlydroppedfromthecodingofMedicaredementia
and not analyzed further.
2.2.2. Other Measures of Cognitive Function. The Mini-
mental State Examination (MMSE) [39] is a 30-point scale,
with scores of 23 or less indicative of some cognitive
impairment and scores of 17 or less indicative of moderate-
to-severe impairment. Subjects who were comatose at the
time of MMSE interview received a score of zero. The MMSE
was available for 1264 subjects (62%) of the 2050 subjects at
baseline.
The MDS-Cognition Scale (MDS-COGS) [40] is a cogni-
tive scale derived from the MDS. The MDS-COGS has an
11-point scale which ranges from 0 = cognitively intact to
10 = very severe impairment based on care provider ratings.
Items include short-term memory, long-term memory, three
orientation items, cognitive skills for daily decision-making,
being understood by others, and self-performance in dress-
ing. The MDS-COGS was available for 1718 subjects (84%)
of the 2050 subjects at baseline.
2.2.3. Two-Year Disposition Measures. For two years follow-
ingthedateofNHadmission,lengthofstay(LOS),discharge
disposition (remained in the NH, discharged to community,
or discharged to another NH,), and death were determined
from a two-year medical record review. Subsequent periods
of hospitalization or rehabilitation were considered part of
the initial NH stay.
2.2.4. Merged Cost Data Measures. Medicare and Medi-
caid data were available from 1992–1997, which permitted
data for at least 9months before NH admission for all
participants, and up to 6 years postadmission for some
participants. For this analysis, we chose to study up to two
years postadmission, since this was the time frame that we
could verify that patients remained in the initial NH. Based
on Medicare claims, measures of cost and utilization of care
were developed. The data set aggregated subjects’ cost and
utilization information contained in the claims records on
a per-person-month (ppm) basis by service type and payer.
The date of nursing home admission was the reference date
(and was included in the ﬁrst month of NH stay).4 International Journal of Alzheimer’s Disease
Table 1: Prevalence and agreement between methods of dementia diagnosis (n = 2050).
Overall Correspondence with panel dementia Correspondence with chart dementia
prevalence Agreement Kappa Sensitivity Speciﬁcity Agreement Kappa Sensitivity Speciﬁcity
Panel 48.0% — — — — 78% 0.55 65% 89%
Chart 36.9% 78% 0.55 65% 89% — — — —
Medicare claims 38.6% 72% 0.43 61% 82% 78% 0.54 73% 82%
Chart or Medicare 48.6% 78% 0.55 77% 78% — — — —
Panel or chart or Medicare 59.5% — — — — — — — —
2.2.5. Covariates. Baseline data were collected by trained
lay interviewers from multiple sources including structured
interviewswithresidents,nursingstaﬀ,andsigniﬁcantothers
(thedesignatedfamilymember,friend,orlegalguardianwho
could provide consent and/or knew the resident best). Base-
line functional status was assessed with a modiﬁed version of
theKatzActivitiesofDailyliving(ADL)Scale,whichmeasures
ability in bathing, dressing, toileting, transferring, feeding,
and continence [41]. Each of 6 ADL domains was asked of
a nursing staﬀ member and scored as dependent or fully
independent; a summary measure indicated the number of
domains in which residents were dependent. Chairfast and
bedfast, were whether a resident was conﬁned to a chair or
bed, were based on information provided from the MDS or
nursing staﬀ interviews; these two variables were included
separately in the model in addition to the number of ADLs
not fully independent.
Age, gender, race, education,a n dmarital status were
obtained from signiﬁcant-other interviews or from charts
if not available from signiﬁcant others. Martial status was
dichotomized as married versus other (widowed, divorced,
and never married). Race was dichotomized as white, non-
Hispanic versus other.
The Resource Utilization Group Score-Case Mix Index
(RUGS CMI) is derived from the MDS forms at NH
admission. Since our data preceded version 2 of the MDS,
we used the original RUG-III classiﬁcation and weighting
derived by Fries and colleagues [42]. A hierarchical grouping
of 7 overall classiﬁcations with 44 groupings was created
from the MDS (ranging from high utilization groups such
as specialized rehabilitation to low utilization groups such
as reduced physical functioning) and a relative nursing unit
weighting was applied. The score is representative of amount
of skilled nursing care required by the resident, with all
weights relative to 1. The RUGS CMI has been used as the
basis of Medicare NH prospective payment to skilled nursing
facilities since late 1998 [43, 44].
Medicare qualiﬁed SNF stays (which require a hospital
admission prior to entry) were inferred from any SNF
payment from Medicare that included the index admission
date. Residents were considered Medicaid eligible at admis-
sion if they had any month with Medicaid eligibility in
the 12months prior to admission or within 30days of NH
admission.
The Diagnostic Cost Group/Hierarchical Coexisting Con-
dition (DCG/HCC), a risk adjuster derived from Medicare
claims, was used to correct for expected costs based on
utilization prior to NH admission. The DCG/HCC is the
basis for the “selected signiﬁcant disease model” that the
Center for Medicare and Medicaid Services (CMS) has used
to set capitation rates for Medicare HMOs since January,
2004 [45]. Our application of the DCG/HCC model used
the 12 months of preadmission Medicare claims to create
a predicted value for Medicare services in the immediate
post-admission year for each study subject. Because our
interest is in ﬁnding the marginal contribution of dementia
to residents’ cost patterns, we explicitly excluded the HCC
category that represents dementias (HCC 49).
2.3. Data Analyses. Three classiﬁcations of dementia (panel,
medical chart, and Medicare claims) were examined to
determineifprevalenceandestimatesofthecostofcarediﬀer
by the ascertainment method. Comparison of agreement
across the methods of ascertainment was calculated using
Cohen’s kappa statistic, which measures the proportion of
agreement beyond the amount expected by chance alone.
Guidelines for interpreting Kappa statistics suggest that
values between 0.81–1.00 indicate almost perfect agreement,
0.61–0.80 substantial agreement, 0.41–0.60 moderate agree-
ment, 0.21–0.40 fair agreement, and values less than 0.21 are
poor or slight agreement [46].
Using the panel’s determination as the criterion variable
“gold standard,” false positive and negatives rates were deter-
mined for each ascertainment method, and hence sensitivity
and speciﬁcity. Mean costs were determined separately for
the true positives, false positives, true negatives, and false
negatives. Post-hoc t-tests within ANOVA were used to
evaluate the equality of the means between preplanned
groups (cases missed versus captured when comparing
methods of ascertainment).
Predictions of cost ratios of dementia versus non-
dementiaresidentsunderdiﬀerentmethodsofascertainment
were estimated. All costs were converted to 1997 current
dollar values to adjust for the eﬀect of inﬂation over time
using the Consumer Price Index (CPI) with December 1997
as the base period.
Intrafacility correlations could lead to underestimates for
the standard errors of regression coeﬃcients. A technique
described by Huber and White [47, 48] and expanded on
by others to include correlated cases [49, 50]w a su s e dt o
account for cluster sampling and provides robust variance
estimates. This technique makes use of a grouping variable,
in this case facility, without requiring its inclusion in the
regression model. It uses a theoretical bootstrap method forInternational Journal of Alzheimer’s Disease 5
correcting the standard errors of the regression coeﬃcients
and can be applied in regression analyses using many
distributions (including gamma). Predictions of cost ratios
of dementia versus non-dementia residents were estimated
in STATA using a generalized linear model (xtgee) with
a log-link and a gamma distribution, utilizing a robust
varianceestimatethatadjustsforwithin-cluster(NHfacility)
correlation [51]. We chose a gamma distribution as this
approach has gained acceptance as the preferred distribution
for costs [52], as costs were right skewed and included
numerous zero values. Predictions of NH length of stay by
diﬀerent ascertainment models were also estimated using a
generalized linear model, but with a Gaussian distribution
assumption.
3. Results
3.1. Prevalence of Dementia under Diﬀerent Methods. Table 1
(1st data column) provides the prevalence of dementia from
the three ascertainment methods. The expert panel found
the highest prevalence of dementia, in 48% of the sample.
The rate from Medicare was 39% and from the medical
chart 37%. Overall, 60% of the sample had some indicator of
dementia, with similar prevalence rates from panel as from a
combined chart plus Medicare claims (48%. versus 49%).
For charts and Medicare claims, the most common
“subtype” of dementia noted was senile dementia (data
not shown), which was found in 29.8% of the sample
by Medicare claims, and 22.9% of the sample by chart.
Alzheimer’s disease was found in 18.1% of the sample by
Medicare claims, and 14.6% of the sample by chart. Vascular
dementia was found in 7.7% of the sample by Medicare
claims and in 3.4% of the sample by chart.
3.2. Agreement between Methods. Table 1 also presents the
concordance between the methods of ascertainment. Agree-
ment between methods was moderate (72–78%; kappas
0.43–0.55), with the highest concordance between NH chart
and the panel. The use of a combined chart and Medicare
claim determination had the highest sensitivity (77%) with
the panel determination, while the chart alone had the
highest speciﬁcity (89%).
3.3. Diﬀerences in Dementia Cases by Ascertainment Method.
Table 2 presents the diﬀerences in dementia cases “captured”
versus “missed” by each ascertainment method. The “all
methods” cases looked at dementia and non-dementia by
combining all three methods; if any method noted dementia
it was considered a dementia case. Signiﬁcant baseline
diﬀerences were found for age, ADL, chairfast, bedfast,
DCG/HCC,RUGSCMI,Medicarequaliﬁedstay,MMSE,and
MDSCOGS. Signiﬁcant diﬀerences were also found for NH
length of stay, death, and discharge home. Panel dementia
cases missed by claims or chart were signiﬁcantly older
age, more ADL impaired, more chairfast, less bedfast, more
impaired on MMSE and MDSCOGS, had longer NH length
of stay, were less likely to die in ﬁrst 90 days, and were less
likely to be discharged home. Dementia cases captured by
Medicare had the highest DCQ/HCC (predicted utilization),
were more likely admitted as a Medicare postacute qualiﬁed
stay, and were the least impaired on the MMSE. Chart
dementia cases captured had the lowest RUGS CMI index
(indicating less need for skilled care).
3.4. Cost Ratios and NH Length of Stay by Method of
Ascertainment. Table 3 shows the average PPM Medicare
costsafteradmissionandNHlengthofstaydiﬀerencesbythe
three dementia ascertainment methods. Estimated Medicare
costs per month were lower for those with dementia
comparedtothosewithoutdementiaunderallascertainment
methods.Theratiosfordementia/non-dementiacostsvaried
by method, such that the panel and chart estimated relative
costs ppm of 0.61-0.62, while the claims estimated dementia
cost ppm was 0.77. Adjustment for covariates to account for
demographics,functionalimpairment,DCG/HCCpredicted
costs, and qualiﬁcation for Medicaid or Medicare postacute
stay did bring the ratios slightly closer to 1.00 (0.65–
0.80), but did not eliminate the statistically signiﬁcant lower
costs for dementia cases. In contrast, dementia cases had
signiﬁcantlyhigheroverallNHLOSunderallmethods.Panel
dementia cases had the highest overall NH length of stay.
3.5. Diﬀerences by Ascertainment Method in Medicare Cost
Categories. Table 4 shows the impact of dementia by ascer-
tainment method across the Medicare cost categories. In
general, all the cost ratios are lower than 1.0, which indicates
lower costs for dementia across all ascertainment methods
and cost categories. The “other” cost category (which
includes outpatient, home health, durable medical equip-
ment, and hospice) has the lowest costs for dementia relative
to non-dementia, and this magnitude is similar across all
the ascertainment methods. Inpatient hospitalization costs
show the greatest diﬀerences in magnitude by ascertainment
methods, such that a diagnosis of dementia ascertained by
Medicare claims estimated similar inpatient hospital costs
among residents with and without dementia, whereas other
ascertainment methods showed lower inpatient hospital
costs among residents with dementia.
3.6. Medicare Costs by Medicare Qualiﬁed SNF Stay. Table 5
examines whether the impact of dementia ascertainment
method is diﬀerent by whether the resident enters under a
Medicare Qualifying (postacute) stay (in which NH care is
reimbursed by Medicare). The ﬁrst 90 days is also examined
separately, since Medicare directly reimburses SNF stays
during that time period. Similar patterns are seen for PPM
costs over the whole 2-year NH stay and in the ﬁrst 90 days.
Overall, the impact of dementia on lower Medicare costs
is greater for those not entering under a qualifying stay;
ratios for those entering under a qualiﬁed stay are close to
1.0. There is much consistency across methods, although the
Medicare claims diagnosis of dementia does provide a more
similar cost ratio (closer to 1.0) under a nonqualifying stay
than other methods.6 International Journal of Alzheimer’s Disease
Table 2: Resident characteristics of dementia cases, and signiﬁcance of diﬀerences, by ascertainment method.
Mean or percent Signiﬁcance of diﬀerences
No dementia Dementia cases Comparisons of dementia
missed by method+
Any method Any
method
Panel
captures
Panel
missed
Chart
captures
Chart
missed
Medicare
captures
Medicare
missed
Panel
versus
chart
Panel versus
Medicare
Chart
versus
Medicare
n = 830 n = 1220 n = 984 n = 236 n = 757 n = 463 n = 792 n = 428
Baseline (NH entry)
Age (mean) 80.3 82.4 82.9 80.6 82.5 82.3 82.2 82.9 ∗ ∗∗∗
Education
(mean) 11.3 10.3 10.3 10.1 10.3 10.3 10.1 10.6
Gender %
male 24.8 31.0 30.1 34.7 29.7 33.0 31.4 30.1
Race %
nonwhite 12.8 22.1 22.7 19.9 22.2 22.0 23.1 20.0
Currently
Married % 19.9 26.7 27.2 24.6 28.4 24.0 27.8 24.8
Katz ADL
(mean) 3.1 4.3 4.4 3.5 4.2 4.2 4.3 4.1 ∗∗∗ ∗ ∗
Comorbidity
(mean) 2.7 2.6 2.6 2.7 2.4 2.9 2.5 2.8
Chairfast % 27.0 30.8 31.5 27.4 27.3 36.5 29.3 33.6 ∗∗
Bedfast % 9.3 7.6 5.9 15.2 6.7 9.1 8.0 7.0 ∗ ∗ ∗∗∗
DCG/HCC
(mean) 14,757.1 13,250.2 12,142.5 17,706.9 11,779.8 15,569.3 13,522.4 12,708.8 ∗∗∗ ∗∗∗
RUGS CMI
(mean) 1.09 1.09 1.09 1.13 1.04 1.20 1.09 1.12 ∗∗ ∗ ∗
Medicaid at
admission % 17.8 27.4 27.9 25.0 25.9 29.8 27.8 26.6
Medicare
qualiﬁed
stay %
67.0 45.7 43.9 55.9 40.7 55.1 46.6 46.0 ∗ ∗ ∗∗∗
MMSE
(mean) 24.4 13.7 12.4 22.1 12.3 15.7 13.0 14.9 ∗∗∗ ∗∗∗ ∗
MDSCOGS
(mean) 1.5 4.9 5.2 3.4 5.5 3.9 5.4 4.0 ∗
NH disposition
NH length
of stay
(mean)
204.8 375.8 402.4 265.0 398.4 338.5 380.1 367.9 ∗ ∗ ∗∗∗ ∗
Died ﬁrst 90
days % 15.3 12.1 9.7 22.0 11.7 12.8 12.4 11.5 ∗∗∗ ∗∗∗
Discharge
home (2
years) %
48.5 18.3 15.6 29.3 17.2 20.1 17.7 19.4 ∗∗ ∗∗
+Signiﬁcance of preplanned t-test comparisons of missed dementia cases across methods (dummy coeﬃc i e n tf r o mr e g r e s s i o na n a l y s e s ) .
∗∗∗p <. 001, ∗∗p <. 01, ∗p <. 05.International Journal of Alzheimer’s Disease 7
Table 3: Dementia versus nondementia nursing home cost (per patient month) and length of stay ratios by method of ascertainment.
Ratios: dementia versus non-dementia
Costs PPM
a Costs PPM
a NH LOS
Raw (95% C.I.) adjusted (95% C.I.)
b Raw (95% C.I.)
c
Panel 0.61 (0.53, 0.70) 0.65 (0.52, 0.80) 1.55 (1.40, 1.72)
Chart 0.62 (0.54, 0.72) 0.70 (0.58, 0.86) 1.38 (1.24, 1.52)
Medicare 0.77 (0.66, 0.90) 0.80 (0.67, 0.96) 1.29 (1.18, 1.40)
Chart or medicare 0.70 (0.62, 0.80) 0.78 (0.66, 0.91) 1.38 (1.25, 1.52)
Chart or medicare or panel 0.66 (0.59, 0.74) 0.68 (0.57, 0.81) 1.53 (1.38, 1.70)
aCosts inﬂated to 1997 dollars, models from GEE assuming Gamma distribution for costs. Costs are those incurred in the nursing home up to 24months
after admission and only include those periods in which the patient was in the initial nursing home.
bAdjusted for age, gender, race, marital, ADL, chairfast, bedfast, DCG/HCC, Medicare qualiﬁed stay, and Medicaid status at admission.
cModels from GEE assuming Gaussian distribution for length of stay (LOS).
Table 4: Dementia versus nondementia cost ratios for diﬀerent Medicare cost categories by method of ascertainment.
Adjusted cost ratios PPM (95% conﬁdence intervals)
a : dementia versus non-dementia
Overall SNF Inpatient Hospital Physician Other services
b
Panel 0.65 (0.52, 0.80) 0.68 (0.43, 1.09) 0.75 (0.50, 1.12) 0.74 (0.63, 0.88) 0.52 (0.43, 0.62)
Chart 0.70 (0.58, 0.86) 0.65 (0.44, 0.98) 0.78 (0.56, 1.09) 0.82 (0.72, 0.93) 0.46 (0.36, 0.59)
Medicare 0.80 (0.67, 0.96) 0.69 (0.49, 0.99) 0.96 (0.71, 1.29) 0.85 (0.73, 1.00) 0.54 (0.45, 0.65)
Chart or Medicare 0.78 (0.66, 0.91) 0.64 (0.45, 0.90) 0.94 (0.74, 1.20) 0.86 (0.77, 0.97) 0.51 (0.43, 0.61)
Chart or Medicare or Panel 0.68 (0.57, 0.81) 0.61 (0.40, 0.95) 0.81 (0.60, 1.10) 0.78 (0.68, 0.90) 0.50 (0.43, 0.59)
aCosts inﬂated to 1997 dollars, models from GEE assuming Gamma distribution. Costs are those incurred in the nursing home up to 24months after
admission and only include those periods in which the patient was in the initial nursing home. Cost ratios are adjusted for age, gender, race, marital status,
ADL, chairfast, bedfast, DCG/HCC, Medicare qualiﬁed stay, and Medicaid status at admission.
bOther services include outpatient, home health, durable medical equipment, and hospice costs.
4. Discussion
Previous work from our NH cohort found that costs
for residents with dementia are lower than those without
dementia, and that adjustment for resident characteristics
and costs prior to admission cannot account for these cost
diﬀerences [32]. This paper extends our work on the new
admissions cohort study, by providing direct comparisons
of multiple measures of dementia, including the Medicare
records and NH chart, and examining the impact of these
diﬀering ascertainment methods on estimated costs. This
potentially allows a comparison of ﬁndings from our study
to community sample data (which heavily rely on Medicare
claims for dementia determination) and to NH national
datasets (which rely heavily on NH chart and/or MDS). The
results from this paper demonstrate that the lower costs for
dementia among NH admissions is a robust ﬁnding across
dementia ascertainment methods.
While the cost ratios were similar, there was, however,
only moderate agreement across methods of dementia ascer-
tainment.Thediﬀerencesinoverallprevalenceareimportant
in determining the overall cost (versus relative cost) of
dementia care in NHs. The panel found a higher prevalence
of dementia than any other method of ascertainment; panel
dementia cases had lower relative average PPM costs, but
longer NH length of stay, compared to non-dementia cases.
Medicare claims appear to capture dementia patients with
higher Medicare utilization (DCG/HCC and qualiﬁed stay),
as might be expected since the capture of diagnosis is
dependent on having claims. Panel-detected dementia cases
were signiﬁcantly older age, more ADL impaired, more
chairfast, less bedfast, less cognitively impaired, had longer
NH length of stay, less likely to die in ﬁrst 90 days, and less
likely to be discharged home than those detected by other
methods. This prediction provides additional validity to the
use of our panel process, in that the panel dementia cases
were more likely the long-stay nursing home cases. Chart
dementia cases captured were the least likely to come in
under a Medicare qualiﬁed stay and had the lowest RUGS
CMI index, perhaps indicating less need for skilled care.
One implication of the greater prevalence of dementia
found by panel determination and diﬀerence in the casemix
is that expert or specialist screening for a diagnosis of
dementia on admission to the nursing home might help
nursing home staﬀ to deliver more patient-centered care
and to weigh the potential beneﬁts and harms of health
interventions. However, such an approach would require
signiﬁcant resources and would need to be tested.
Data for this paper were derived using a NH admission
cohort and thus represent the highest cost dementia cases.
Persons who enter a nursing home are, by deﬁnition, more
physically sick and/or functionally disabled than those who
remain in the community. This might explain why our costs
for those with dementia are low relative to non-dementia,
since many of the non-dementia cases are also very ill (as
shown by the higher DCG/HCC means for those without8 International Journal of Alzheimer’s Disease
Table 5: Dementia versus nondementia cost ratios by method of ascertainment by whether admitted to NH under a Medicare qualifying
stay (MQS).
Adjusted cost ratios (95% conﬁdence intervals)
a : dementia versus non-dementia
Overall Costs PPM Costs in the ﬁrst 90 days
MQS Not MQS MQS Not MQS
Panel 0.95 (0.82, 1.09) 0.43 (0.30, 0.60) 0.99 (0.89, 1.11) 0.51 (0.34, 0.74)
Chart 0.93 (0.81, 1.08) 0.50 (0.37, 0.68) 0.94 (0.84, 1.06) 0.52 (0.39, 0.68)
Medicare 0.94 (0.78, 1.12) 0.68 (0.48, 0.97) 0.96 (0.83, 1.10) 0.65 (0.49, 0.87)
Chart or Medicare 0.99 (0.88, 1.12) 0.55 (0.41, 0.75) 0.99 (0.90, 1.09) 0.57 (0.44. 0.73)
Chart or Medicare or Panel 0.93 (0.82, 1.04) 0.47 (0.32, 0.67) 0.97 (0.88, 1.06) 0.55 (0.40, 0.75)
aCosts inﬂated to 1997 dollars, models from GEE assuming Gamma distribution. Costs are those incurred in the nursing home up to 24months after
admission and only include those periods in which the patient was in the initial nursing home. Models adjusted for age, gender, race, marital, ADL, chairfast,
bedfast, DCG/HCC, and Medicaid status at admission.
dementia) and most of our subjects enter the nursing home
through a hospitalization and related postacute qualifying
stay (67% of non-dementia and 46% of dementia cases).
Much previous work has found that most of the higher cost
for dementia care in the community is due to hospitalization
costs [21]. Our previous work has also shown that the lower
costs to NHs for people with dementia are not seen when
looking only at those admitted for a Medicare Qualifying
Skilled Nursing Facility, in which both groups may be more
similar on severity of comorbidities [32].
Although there are potential diﬀerences between the
groups in underlying medical illness, we cannot rule out the
alternative hypothesis that the lower costs for people with
dementiaareduetolowerattentionandtreatmentbecauseof
eitherinabilityofpeoplewithdementiatoverbalizetheircare
needsorbiasestowardspeoplewithdementia.Certainly,that
was our underlying hypothesis in designing the overall study,
although we expected that the lack of treatment would lead
to higher rates of other adverse events (e.g., deaths, serous
infections, and hospitalizations), which has not been seen in
ourdata[14].Furthermore,wewouldhaveexpectedthatthis
diﬀerence to be more pronounced in “recognized” dementia
cases versus those determined from our panel, and none
of our results has shown that the method of determination
aﬀects utilization or outcomes.
T h o s ew h oe n t e rN H sa r em o r el i k e l yt oh a v em a n y
Medicare claims in the year prior to admission, minimizing
the potential selection bias of people not needing/seeking
care being missed. While Taylor et al. [30] recommend at
least 3 years of Medicare data to capture dementia diagnoses,
our data had only 13 months of Medicare claims. However,
the period pre-NH admission is a high intensity medical
use time, so it is less likely that we lacked medical visits in
examining dementia codes.
We used the panel determination of dementia as the
major criterion measure of dementia in our study; however
our diagnosis is certainly not a “gold standard.” Previous
reports from our group have shown this determination to be
asvalidasaclinicianassessment[27];however,anydementia
diagnosis (relying on secondary information and not direct
clinical examination) may not be totally accurate.
It should be considered that the data for this study
was derived from 59 NHs in a single state (Maryland)
and was conducted in 1992–1997, which is before the
implementation of the Medicare NH Prospective Payment
System (PPS) in the US. The NH-PPS has more tightly
linked the reimbursement for postacute skilled care (which
the majority of the sample was admitted under) to the level
of rehabilitation care provided and the medical needs of the
patient. While dementia and related ADL impairment are
a part of the current reimbursement hierarchy, the level of
reimbursement for solely dementia cases is relatively low
and remains so even in the newest reﬁnement of the RUGS
[53]. The expectation of relatively lower costs for those with
dementia as their primary reason for NH care was based
on work done on nursing time [42], the ﬁndings of which
are in line with the lower relative Medicare costs we found.
However, our previous ﬁndings also showed that dementia
cases are more similar in costs to non-dementia cases if they
entered for a Medicare Qualiﬁed SNF stay [32].
Our cost data was estimated from 1992 to 1997, and we
standardized the absolute cost amounts to December 1997
dollars. Certainly these estimates would be much higher
in 2009, given that the Consumer Price Index has risen
133.7% from December 1997 to June 2009 [54]. However,
most of our data is presented as relative rates, which should
not be impacted by inﬂation. Relatedly, as noted in the
introduction, most cost reports of the caring for people with
dementia date to the early 1990s and more current estimates
of these costs would be valuable for researchers and policy
analysts.
Since the time of the study, the use of assisted living
facilities for care, especially for dementia, has increased [22].
Many assisted living facilities specialize in care for residents
with mild or moderate dementia. It is likely that many of
the mild low-cost dementia cases included in our sample
(and more likely to be picked up by the panel) may now
have care provided in these alternative settings, which might
bringthecostratiosfordementiaversusnon-dementiacloser
to 1. The ﬁnding of more similar cost ratios for between
dementia and non-dementia cases admitted as a postacute
qualifying stay might be more appropriate to this post-PPS
care environment, but that remains an empirical question to
be answered by other data.
Also, there may have been changes over time in attention
and coding for dementia in Medicare claims records sinceInternational Journal of Alzheimer’s Disease 9
1992 [55, 56]. In September 2001, CMS issued a special
directive due to concerns about the limiting of certain claims
for persons with dementia [57]. Reimbursement for many
claims during the time period we studied did not require
secondary diagnoses to be listed, so there is certainly concern
that the Medicare claims undercount dementia cases.
One ﬁnding that was consistent across ascertainment
methods is that dementia patients have longer lengths of NH
stay. Thus, while dementia cases have lower per month costs,
their increased length of stay translates to similar costs per
total episode of NH care. Policy makers and managed care
plans should consider this tradeoﬀ when determining how
to set rates for dementia cases.
In conclusion, we found that most readily available
ascertainment methods for diagnosing dementia in NHs
vastly undercount the number of dementia cases admitted
to nursing homes and may miss those cases most likely
to remain the longest in the NH environment. However,
the per month costs while in the NH were consistently
lower among dementia cases, as compared to non-dementia
admissions, across all methods of dementia ascertainment.
Future research should verify that this pattern remains given
the growth of alternate long-term care settings and changes
in Medicare reimbursement.
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